Australia markets open in 56 minutes

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.3198+0.0098 (+0.75%)
At close: 03:53PM EST
1.4400 +0.12 (+9.11%)
After hours: 04:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 22.03M
Enterprise value -17.32M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.58
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.02

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-76.27%
S&P500 52-week change 3-14.68%
52-week high 37.6500
52-week low 30.9500
50-day moving average 31.1939
200-day moving average 31.7114

Share statistics

Avg vol (3-month) 3181.66k
Avg vol (10-day) 369.13k
Shares outstanding 515.97M
Implied shares outstanding 6N/A
Float 88.95M
% held by insiders 15.82%
% held by institutions 132.52%
Shares short (14 Nov 2022) 4162.8k
Short ratio (14 Nov 2022) 41.59
Short % of float (14 Nov 2022) 41.08%
Short % of shares outstanding (14 Nov 2022) 41.02%
Shares short (prior month 13 Oct 2022) 432.34k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-39.72%
Return on equity (ttm)-80.20%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-14.37M
Diluted EPS (ttm)-1.9300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)39.43M
Total cash per share (mrq)2.47
Total debt (mrq)78.2k
Total debt/equity (mrq)0.20
Current ratio (mrq)10.45
Book value per share (mrq)2.38

Cash flow statement

Operating cash flow (ttm)-14.58M
Levered free cash flow (ttm)-11.34M